Non-invasive assessment of lung remodeling in patients with idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) using [11C]-Nintedanib or [18F]-FLT PET imaging.

Non-invasive assessment of lung remodeling in patients with idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) using [11C]-Nintedanib or [18F]-FLT PET imaging. - Imaging the primary disease process in IPF and PAH

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44254

Enrollment

Registered

2017-12-13

Start date

2018-05-28

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopatic pulmonary fibrosis pulmonary arterial hypetrension

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: 1. Diagnosis of IPF, according to ATS/ERS guidelines (ref Raghu AJRCCM 2011) or Diagnosis of PAH, according to ESC/ERS guidelines (ref: Galie ERJ 2015) or Unaffected BMPR2 mutation carrier or Normal control subjects 2. Age >18 and

Exclusion criteria

Exclusion criteria: - Claustrophobia - Inability to provide informed consent - In case of IPF patients: pulmonary hypertension suspected by echocardiography or proven by right heart catheterization - In case of PAH patients: TLC

Design outcomes

Primary

Measure	Time frame
Uptake of [11C]-Nintedanib or [18F]-FLT in the lung of IPF or IPAH patients. Secundary study	—

Secondary

Measure	Time frame
none	—

Countries

Netherlands

Outcome results